The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The association of centromere amplification and response to trastuzumab in HER2+ metastatic breast cancer.
 
Charlotte Andrieu
Patents, Royalties, Other Intellectual Property - PATENT APPLICATION NUMBER 2218279.4 - UK Intellectual Property Office
 
Dalal Al-Sultan
No Relationships to Disclose
 
Laura Ivers
No Relationships to Disclose
 
Jose Javier Berenguer Pina
No Relationships to Disclose
 
Darko Skrobo
No Relationships to Disclose
 
Josephine Ballot
No Relationships to Disclose
 
Alex J. Eustace
No Relationships to Disclose
 
Cecily Quinn
Honoraria - Exact Sciences; Medscape
 
Giuseppe Gullo
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
Patents, Royalties, Other Intellectual Property - PATENT APPLICATION NUMBER 2218279.4 - UK Intellectual Property Office
 
Naomi Walsh
Patents, Royalties, Other Intellectual Property - PATENT APPLICATION NUMBER 2218279.4 - UK Intellectual Property Office
 
John Crown
Employment - OncoAssure; OncoMark
Stock and Other Ownership Interests - OncoAssure; OncoMark
Honoraria - AstraZeneca; MSD Oncology; Pfizer; Pierre Fabre
Consulting or Advisory Role - AstraZeneca; MSD Oncology
Speakers' Bureau - Pfizer
Research Funding - BMS GmbH & Co. KG (Inst); MSD Oncology (Inst); Novartis (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - WO2020011770 (A1) - A method of predicting response to treatment in cancer patients
Travel, Accommodations, Expenses - Astrazeneca; Daiichi Sankyo Europe GmbH; MSD; Pfizer; Regeneron; Roche